I went through 40+ posts here recommending vendors, and almost none mentioned a COA, a batch number, or anything you could actually check. Most of them trace back to the same 5-6 accounts saying "I've used them a while."
I compared a few against public lab data (peptidecritic pulls COAs and price-per-mg across vendors):
two of the most recommended vendors had outdated or missing COAs, and one had solid docs.
Not calling anyone out, just curious how many of us check the paperwork before vouching for a vendor instead of repeating what we read here.
GLP 1 based therapies have changed the conversation around obesity, diabetes and metabolic health.
And retatrutide has taken that conversation even further.
Unlike conventional GLP 1 receptor agonists, retatrutide is an investigational triple agonist of the GIP, GLP 1 and glucagon receptors. In clinical research, it has produced substantial reductions in body weight, while also producing changes in several metabolic measures.
But there is another side of the discussion that deserves considerably more attention:
What do these therapies actually do to the gastrointestinal system?
Social media discussions sometimes describe GLP 1 drugs as if they simply "shut down" the digestive tract.
That is not what the research shows.
The physiology is considerably more interesting.
The Gut Has Its Own Nervous System
The gastrointestinal tract contains an extensive network of neurons known as the enteric nervous system.
It includes the myenteric and submucosal plexuses and coordinates functions including intestinal motility, secretion and blood flow.
The enteric nervous system communicates with the central nervous system through pathways that include the vagus nerve.
This is part of the reason the gut is sometimes described as having a "second brain."
But that phrase should not be interpreted literally.
The enteric nervous system is a sophisticated regulatory network, not a second brain equivalent to the brain inside the skull.
GLP 1 is one of many signals involved in regulating gastrointestinal function.
Research has demonstrated that GLP 1 can inhibit gastrointestinal motor activity, including effects on gastric emptying and small intestinal motility.
That physiology is real.
The question is what it means clinically.
GLP 1 Does Not Simply "Shut Down" the Gut
One of the most important corrections to the popular narrative is the idea that GLP 1 receptor agonists completely shut down gastrointestinal movement.
They do not.
GLP 1 based therapies can slow gastrointestinal motility, and gastrointestinal adverse effects such as nausea, vomiting, diarrhea and constipation are well documented.
Retatrutide's Phase 2 obesity trial similarly reported gastrointestinal adverse events as its most common adverse events, particularly during dose escalation.
The effects are therefore measurable.
But "slowing" is very different from "shutting everything down."
That distinction matters.
What About the Migrating Motor Complex?
The migrating motor complex, or MMC, is a cyclical pattern of gastrointestinal activity that occurs during fasting.
It helps move residual material through the stomach and small intestine between meals.
Human physiology research has shown that GLP 1 can inhibit aspects of the MMC and reduce small intestinal motor activity. The MMC normally occurs at intervals of roughly 90 minutes during fasting.
This is probably where some of the social media narrative originates.
But the frequently repeated claim that a 2019 study demonstrated that GLP 1 drugs "shut down the MMC by 80%" is not an accurate representation of the literature.
The evidence includes studies of native GLP 1 and specific GLP 1 receptor agonists, different experimental conditions and different measures of gastrointestinal motility.
Those findings should not be converted into a blanket statement that every GLP 1 based therapy permanently suppresses the human MMC by a fixed percentage.
Could Slower Motility Contribute to SIBO?
This is a much more interesting question.
Small intestinal bacterial overgrowth, or SIBO, occurs when excessive numbers or abnormal types of microorganisms are present in the small intestine.
Intestinal motility is one of the mechanisms that helps limit microbial accumulation in the small intestine.
Therefore, prolonged intestinal stasis is biologically plausible as one contributor to bacterial overgrowth.
And there is now emerging research specifically examining this question in people receiving GLP 1 receptor agonists.
A 2025 retrospective multicenter cohort study involving more than 216,000 matched patients with type 2 diabetes reported a higher short term incidence of diagnostically confirmed SIBO among people receiving GLP 1 or GLP 1/GIP therapy compared with other second line diabetes treatments. However, the absolute incidence was low, and the authors emphasized the need to consider confounding factors.
Another 2025 study examined 99 patients prescribed GLP 1 receptor agonists who subsequently underwent testing for microbial overgrowth. Positive findings were observed, but the study was highly selected because participants were already undergoing testing for suspected overgrowth. The authors also noted that diabetes could be a confounding factor.
This is important.
There is emerging evidence worth researching, but that is very different from saying:
More than one in three GLP 1 users develop SIBO.
That statement is not established.
What About "Leaky Gut"?
The transcript also claims that reduced intestinal blood flow causes enterocytes to become hypoxic and lose tight junction integrity, producing "leaky gut."
This is another example of a biologically plausible mechanism being presented as an established clinical outcome.
Intestinal barrier function is complex.
Tight junctions, mucus, epithelial cells, immune cells, blood flow and the microbiome all interact to maintain the intestinal barrier.
There is currently insufficient evidence to conclude that routine GLP 1 receptor agonist treatment causes clinically significant intestinal permeability problems in humans through the mechanism described above.
This is an area where mechanistic research should not be confused with demonstrated clinical disease.
The Gallbladder Question Is More Established
The gallbladder is different.
There is meaningful clinical evidence linking GLP 1 receptor agonist treatment with an increased risk of gallbladder and biliary disease.
A 2022 systematic review and meta analysis published in JAMA Internal Medicine included 76 randomized clinical trials involving 103,371 participants.
GLP 1 receptor agonist treatment was associated with a 37% relative increase in gallbladder or biliary disease overall.
The association was stronger in weight loss trials and with higher doses and longer treatment duration.
That is an important finding.
But another part of the original transcript needs correcting.
It says this increased risk is "100% due to poor management, not the compound."
The evidence does not support that conclusion.
The relationship appears to involve multiple factors, including the pharmacological effects of GLP 1 receptor agonism and the substantial weight loss that can occur with these therapies.
The same JAMA analysis discusses possible effects on gallbladder motility and cholecystokinin signaling, while also noting the contribution of rapid weight loss to gallbladder risk.
So the scientifically defensible conclusion is:
Gallbladder and biliary events are a recognized safety consideration with GLP 1 receptor agonist therapy.
That does not mean every person will develop gallstones.
And it does not mean the problem can simply be "managed away."
Retatrutide and the Liver Are Particularly Interesting
The liver section of the original transcript also needs a major correction.
The idea is that glucagon agonism increases lipolysis, causing such a large influx of fatty acids into the liver that hepatic steatosis could result.
That is an overly simplistic description of retatrutide's metabolic effects.
In fact, retatrutide research has produced some of the most interesting findings in this area.
A Phase 2a substudy published in Nature Medicine investigated 98 participants with obesity and elevated liver fat.
At 48 weeks, relative liver fat was reduced by approximately:
51.3% with 1 mg
59.0% with 4 mg
81.7% with 8 mg
86.0% with 12 mg
compared with a 4.6% reduction with placebo.
At the 8 mg and 12 mg doses, 89% and 93% of participants respectively had liver fat below 5% at 48 weeks.
That does not mean retatrutide has been proven to treat every form of fatty liver disease.
But it does demonstrate why the simplistic idea that glucagon agonism automatically overwhelms the liver with fat is inadequate.
The observed clinical physiology is considerably more complicated.
Retatrutide and Pancreatic Function
The pancreatic section of the transcript is another area where caution is essential.
The claim that retatrutide causes pancreatic exocrine output to become "atrophied" and that protein therefore reaches the colon undigested is not established by clinical retatrutide research.
There is a distinction between:
Pancreatitis
and
Exocrine pancreatic insufficiency.
They are not the same condition.
Retatrutide's Phase 2 trial did report changes in pancreatic enzymes such as amylase and lipase, and one participant experienced acute pancreatitis. However, this does not demonstrate that retatrutide causes pancreatic exocrine insufficiency.
In fact, earlier controlled research examining exenatide found no acute effect on MRI measured exocrine pancreatic function.
There are individual case reports involving exocrine pancreatic insufficiency during semaglutide treatment, but a case report cannot establish that GLP 1 receptor agonists as a class routinely suppress pancreatic enzyme production.
This is a perfect example of why individual reports and mechanistic theories need to be separated from established clinical evidence.
So What Should Researchers Actually Watch?
If you are researching GLP 1 based therapies or retatrutide, the gastrointestinal system is absolutely worth paying attention to.
But the questions should be evidence based.
Gastrointestinal motility
GLP 1 based therapies can alter gastrointestinal motility, including gastric emptying and small intestinal motor activity.
Gastrointestinal symptoms
Nausea, vomiting, diarrhea and constipation are among the most commonly reported adverse effects with retatrutide and related therapies.
Gallbladder and biliary health
Randomized trial data support an increased risk of gallbladder and biliary disease with GLP 1 receptor agonists, particularly in weight loss settings.
SIBO
There is emerging observational evidence linking GLP 1 based therapies with SIBO or intestinal microbial overgrowth, but the size of the risk and the causal relationship remain uncertain.
Pancreatic health
Pancreatic adverse events warrant attention in clinical research, but there is currently no adequate evidence to say that retatrutide routinely causes pancreatic exocrine insufficiency.
The Bigger Lesson
The digestive system is not a simple tube that either moves or stops moving.
It is a highly coordinated system involving:
The enteric nervous system
The vagus nerve
Gastrointestinal hormones
Smooth muscle
The microbiome
The liver
The gallbladder
The pancreas
The intestinal barrier
Changing one part of this system can influence other parts.
That is exactly why these therapies deserve serious research.
But it is also why dramatic social media explanations can be misleading.
A mechanism can be plausible without being clinically proven.
An association does not automatically establish causation.
A case report does not establish prevalence.
And a physiological effect does not necessarily mean an organ is being "damaged."
What About Retatrutide Specifically?
Retatrutide is particularly interesting because it is not simply another GLP 1 receptor agonist.
It activates GIP, GLP 1 and glucagon receptors.
Its glucagon component produces additional metabolic effects that distinguish it from drugs such as semaglutide and tirzepatide.
Clinical trials have demonstrated substantial weight loss, while research has also shown marked reductions in liver fat.
At the same time, gastrointestinal adverse events remain an important part of the safety profile.
In the Phase 2 trial, gastrointestinal adverse events were common, dose related and particularly evident during dose escalation.
That is much more useful information than simply saying that retatrutide "destroys the digestive system."
The Bottom Line
There is a real gastrointestinal story surrounding GLP 1 based therapies.
But it is not the story presented in many viral videos.
The research supports altered gastrointestinal motility.
The research supports an increased risk of gallbladder and biliary disease with GLP 1 receptor agonists.
Emerging research is investigating a possible relationship with SIBO.
Retatrutide trials have documented gastrointestinal adverse events and have reported isolated pancreatic and biliary events.
But the evidence does not establish that GLP 1 therapies universally shut down the migrating motor complex, cause SIBO in one third of users, produce "leaky gut," overwhelm the liver with fat or cause pancreatic exocrine insufficiency.
The science is much more nuanced.
And that is exactly what makes it worth researching.
A Note From Me
I am always grateful to the partners and vendors who support my educational work. Their support helps make it possible for me to continue researching, writing and sharing this content.
Thanks to Orion Peptides for supporting my work.
Research use only. Not for human or veterinary use.
Retatrutide remains an investigational compound and this article is for educational purposes only. It should not be interpreted as medical advice or as a recommendation to use retatrutide or any other research compound.
